Immune Enzymes Tied to Nerve Damage Risk

Credibility

Interest

Key Takeaway

Higher levels of enzymes released by a type of white blood cell (neutrophils) were linked to a greater chance of developing ALS, suggesting immune activity can harm nerve fibers before symptoms start.

What They Found

Researchers measured six enzymes that neutrophils (a type of immune cell) release and found people who later got ALS had higher levels of these enzymes before symptoms began. Higher enzyme levels were tied to a higher risk of developing ALS, meaning the immune system was active early on. The study found a steady relationship between these enzyme levels and higher amounts of a nerve-injury marker called neurofilament light chain (NfL); think of NfL as a smoke signal that shows nerve fibers are being damaged. Two enzymes, myeloperoxidase (MPO) and S100A12, seemed to raise ALS risk partly by causing this nerve fiber damage—like how rain can both make a road slippery and also wash away its top layer. The authors suggest these enzymes give a clue about how neutrophils might start or speed up nerve damage and could be targets for future treatments.

Who Should Care and Why

People with MS and their caregivers may care because both MS and ALS involve damage to nerve fibers; understanding immune-driven nerve injury helps compare how different immune cells affect nerves. If immune cells can damage nerves before symptoms, it’s similar to finding a slow leak in a house pipe before the flood—earlier detection and treatment might protect nerves. Neurologists and MS care teams might learn from this work when thinking about how different immune responses affect disease progression or treatment side effects. Patients interested in research should know this doesn’t mean the same enzymes cause MS, but it highlights how immune activity can hurt nerves and why monitoring inflammation matters. Caregivers can use the idea to support early communication with clinicians about new or worsening symptoms, since immune changes may happen before symptoms are obvious.

Important Considerations

This study focused on ALS, not MS, so we can’t assume the same enzymes play the same role in MS. The findings show association (a link) but do not prove these enzymes directly cause ALS—other factors might be involved. Also, results came from a research population and need more studies before changing treatments or testing these enzymes in routine care.

Categories:

Early Research MS Progression MS Genetics

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News